EU regulator rejects Alzheimer’s drug lecanemab
It said the benefits of the treatment did not outweigh the risk of serious side effects.
The post EU regulator rejects Alzheimer’s drug lecanemab appeared first on News and Blog Center | RSS Feed Syndication.
